We are slightly increasing our 2026 and 2027 projections after meeting with Betterware de Mexico management, with the company completing the Tupperware LatAm acquisition on June 2nd. We believe, even more so after the deal is completed, the acquisition of Tupperware LatAm will offer a multi-year material top and bottom line growth path for the company. Further, we also believe both the Betterware and JAFRA divisions still have material growth opportunities ahead of them. As such, and with BWMX yielding almost 7% and trading at 6.2X our conservative 2027 EPS , we view the risk/reward as highly impressive.
09 Jun 2026
BWMX: Mgmt. Meetings: Tupperware Deal Completed; Remain Upbeat; Reiterate Buy, PT
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
BWMX: Mgmt. Meetings: Tupperware Deal Completed; Remain Upbeat; Reiterate Buy, PT
Medifast (MED:NYSE), 0 | Medifast, Inc. (MED:NYS), 0 | Betterware de Mexico, S.A.P.I. de C.V. (BWMX:NYS), 0 | DD3 Acquisition Corp (DDMX:NYSE), 0 | Nu Skin Enterprises (NUS:NYSE), 0 | Nu Skin Enterprises, Inc. Class A (NUS:NYS), 0
- Published:
09 Jun 2026 -
Author:
Eric Beder -
Pages:
5 -
We are slightly increasing our 2026 and 2027 projections after meeting with Betterware de Mexico management, with the company completing the Tupperware LatAm acquisition on June 2nd. We believe, even more so after the deal is completed, the acquisition of Tupperware LatAm will offer a multi-year material top and bottom line growth path for the company. Further, we also believe both the Betterware and JAFRA divisions still have material growth opportunities ahead of them. As such, and with BWMX yielding almost 7% and trading at 6.2X our conservative 2027 EPS , we view the risk/reward as highly impressive.